Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID)

K. Davies, J. Lawrence, C. Berry, G. Davis, H. Yu, B. Cai, E. Gonzalez, I. Prantner, A. Kurcz, I. Macovei, H. Pituch, E. Nováková, O. Nyč, B. Gärtner, FK. Berger, M. Oleastro, OA. Cornely, MJGT. Vehreschild, L. Pedneault, M. Wilcox,

. 2020 ; 8 (-) : 293. [pub] 20200717

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021959

Background: There are inconsistent data on the risk factors for Clostridium difficile infection (CDI) in the literature. Aims: To use two C. difficile infection (CDI) case-control study groups to compare risk factors in hospitalized patients with diarrhea across different countries. Methods: A multi-center group of CDI cases/controls were identified by standardized testing from seven countries from the prior EUropean, multi-center, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhea (EUCLID). A second group of CDI cases/controls was identified from a single center in Germany [parallel study site (PSS)]. Data were extracted from the medical notes to assess CDI risk factors. Univariate analyses and multivariate logistic regression models were used to identify and compare risk factors between the two groups. Results: There were 253 and 158 cases and 921 and 584 controls in the PSS and EUCLID groups, respectively. Significant variables from univariate analyses in both groups were age ≥65, number of antibiotics (OR 1.2 for each additional antibiotic) and prior hospital admission (all p < 0.001). Congestive heart failure, diabetes, admission from assisted living or Emergency Department, proton pump inhibitors, and chronic renal disease were significant in PSS (all p < 0.05) but not EUCLID. Dementia and admitted with other bacterial diseases were significant in EUCLID (p < 0.05) but not PSS. Following multivariate analyses, age ≥ 65, number of antibiotics and prior hospital admission were consistently identified as CDI risk factors in each individual group and combined datasets. Conclusion: Our results show that the same CDI risk factors were identified across datasets. These were age ≥ 65 years, antibiotic use and prior hospital admission. Importantly, the odds of developing CDI increases with each extra antibiotic prescribed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021959
003      
CZ-PrNML
005      
20201204093440.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpubh.2020.00293 $2 doi
035    __
$a (PubMed)32766196
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Davies, Kerrie $u Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom.
245    10
$a Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID) / $c K. Davies, J. Lawrence, C. Berry, G. Davis, H. Yu, B. Cai, E. Gonzalez, I. Prantner, A. Kurcz, I. Macovei, H. Pituch, E. Nováková, O. Nyč, B. Gärtner, FK. Berger, M. Oleastro, OA. Cornely, MJGT. Vehreschild, L. Pedneault, M. Wilcox,
520    9_
$a Background: There are inconsistent data on the risk factors for Clostridium difficile infection (CDI) in the literature. Aims: To use two C. difficile infection (CDI) case-control study groups to compare risk factors in hospitalized patients with diarrhea across different countries. Methods: A multi-center group of CDI cases/controls were identified by standardized testing from seven countries from the prior EUropean, multi-center, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhea (EUCLID). A second group of CDI cases/controls was identified from a single center in Germany [parallel study site (PSS)]. Data were extracted from the medical notes to assess CDI risk factors. Univariate analyses and multivariate logistic regression models were used to identify and compare risk factors between the two groups. Results: There were 253 and 158 cases and 921 and 584 controls in the PSS and EUCLID groups, respectively. Significant variables from univariate analyses in both groups were age ≥65, number of antibiotics (OR 1.2 for each additional antibiotic) and prior hospital admission (all p < 0.001). Congestive heart failure, diabetes, admission from assisted living or Emergency Department, proton pump inhibitors, and chronic renal disease were significant in PSS (all p < 0.05) but not EUCLID. Dementia and admitted with other bacterial diseases were significant in EUCLID (p < 0.05) but not PSS. Following multivariate analyses, age ≥ 65, number of antibiotics and prior hospital admission were consistently identified as CDI risk factors in each individual group and combined datasets. Conclusion: Our results show that the same CDI risk factors were identified across datasets. These were age ≥ 65 years, antibiotic use and prior hospital admission. Importantly, the odds of developing CDI increases with each extra antibiotic prescribed.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lawrence, Jody $u Vaccine Research and Development, Pfizer Inc., Pearl River, NY, United States.
700    1_
$a Berry, Claire $u Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom.
700    1_
$a Davis, Georgina $u Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom.
700    1_
$a Yu, Holly $u Vaccine Research and Development, Pfizer Inc., Pearl River, NY, United States.
700    1_
$a Cai, Bing $u Vaccine Research and Development, Pfizer Inc., Pearl River, NY, United States.
700    1_
$a Gonzalez, Elisa $u Vaccine Research and Development, Pfizer Inc., Pearl River, NY, United States.
700    1_
$a Prantner, Ida $u Department of Hospital Epidemiology and Hygiene, National Center for Epidemiology, Budapest, Hungary.
700    1_
$a Kurcz, Andrea $u Department of Hospital Epidemiology and Hygiene, National Center for Epidemiology, Budapest, Hungary.
700    1_
$a Macovei, Ioana $u Cantacuzino National Medico-Military Institute for Research and Development, Bucharest, Romania.
700    1_
$a Pituch, Hanna $u Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Nováková, Elena $u Department of Microbiology and Immunology in Jessenius Faculty of Medicine Martin, Comenius University Bratislava, Martin, Slovakia.
700    1_
$a Nyč, Otakar $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia.
700    1_
$a Gärtner, Barbara $u Germany National Reference Centre for Clostridiodies Clostridium difficile, Institute of Medical Microbiology and Hygiene, Saarland University of Medical Center, Homburg, Germany.
700    1_
$a Berger, Fabian K $u German National Reference Center for Clostridioides (Clostridium) Difficile, Institute of Medical Microbiology and Hygiene, Saarland University, Saarbrücken, Germany.
700    1_
$a Oleastro, Monica $u Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
700    1_
$a Cornely, Oliver A $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Department I of Internal Medicine, Clinical Trials Center Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
700    1_
$a Vehreschild, Maria J G T $u Department I of Internal Medicine, Germany and German Centre for Infection Research (DZIF), University Hospital of Cologne, Partner Site Bonn-Cologne, Cologne, Germany.
700    1_
$a Pedneault, Louise $u Vaccine Research and Development, Pfizer Inc., Pearl River, NY, United States.
700    1_
$a Wilcox, Mark $u Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom.
773    0_
$w MED00186211 $t Frontiers in public health $x 2296-2565 $g Roč. 8, č. - (2020), s. 293
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32766196 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204093438 $b ABA008
999    __
$a ind $b bmc $g 1591667 $s 1112631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c - $d 293 $e 20200717 $i 2296-2565 $m Frontiers in public health $n Front Public Health $x MED00186211
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace